Trump and Merck KGaA Strike Major Deal to Cut IVF Drug Prices Nationwid
Trump and Merck KGaA have announced a groundbreaking agreement to reduce IVF drug prices across the U.S., aiming to make fertility treatments more affordable for families.
Live Update: Historic Agreement Offers Up to 84% Discount on Key Fertility Medications; Savings to Be Available via New 'TrumpRx' Platform
(Washington, D.C.) – October 17, 2025 – In a significant step aimed at making fertility care drastically more affordable for American families, President Donald J. Trump and Germany-based pharmaceutical giant Merck KGaA (through its U.S. arm, EMD Serono) announced a landmark deal on Thursday to cut the cost of essential In Vitro Fertilization (IVF) drugs. The agreement, framed by the White House as a critical component of its "Most-Favored-Nation" drug pricing campaign, promises massive direct-to-consumer savings for those navigating the often prohibitive financial journey of IVF.
The announcement positions fertility treatment affordability at the forefront of the administration's healthcare agenda, fulfilling a key campaign promise to expand access to IVF.
Key Provisions of the Groundbreaking Deal
The core of the new agreement is a commitment by EMD Serono, a world leader in fertility treatments, to offer significantly reduced prices on its most widely used IVF medications directly to patients.
1. Massive Direct-to-Consumer Discounts
The centerpiece of the deal is the deep discount offered on three of the company's leading IVF drugs:
Gonal-f (follitropin alfa injection)
Ovidrel (choriogonadotropin alfa injection)
Cetrotide (cetrorelix acetate for injection)
According to Merck KGaA, when these three therapies are used together in a typical IVF protocol, eligible patients will receive a combined discount of up to 84% off list prices if purchasing directly. Senior administration officials estimate that the cuts will save families approximately $2,200 per IVF cycle.
2. Launch of the TrumpRx Platform
The discounted drugs will be made available to consumers with a valid prescription through a new direct-to-consumer website, TrumpRx.gov, which the White House plans to launch in early 2026. This platform is the administration's latest effort to bypass traditional pharmaceutical distribution channels and insurance hurdles to provide lower-cost medicines directly from manufacturers. Merck KGaA is the third major pharmaceutical company, following Pfizer and AstraZeneca, to sign an agreement to list its products on the platform.
3. Trade-Off: Tariff Relief and Expedited Review
In a quid pro quo mirroring the administration’s strategy with other drug makers, EMD Serono is receiving two major incentives in exchange for the price cuts:
Tariff Exemption: EMD Serono has entered an agreement with the U.S. Commerce Department to exclude its pharmaceutical products and ingredients from potential future Section 232 tariffs, provided the company commits to investing in future U.S. manufacturing and research.
Expedited FDA Review: The company plans to file its fertility drug, Pergoveris, for review under the FDA Commissioner's National Priority Voucher (CNPV) program. This program is designed to reduce the drug review timeline from the typical 10-12 months to just 1-2 months, potentially bringing the combination therapy to the U.S. market much faster.
Wider Impact on Fertility Access and Policy
The deal with Merck KGaA is part of a broader, two-pronged approach unveiled by the White House to tackle the national infertility crisis, which comes amid historically low U.S. birth rates and high treatment costs.
Encouraging Employer Coverage
In addition to the drug pricing deal, the administration is taking steps to encourage employers to offer fertility benefits. The U.S. Treasury, Labor, and Health and Human Services departments will issue guidance to make it easier and clearer for companies, particularly small businesses, to offer supplemental, standalone insurance plans specifically for fertility—akin to vision or dental coverage.
"This is about giving hope and opportunity back to the countless people who dream of having a child," President Trump stated, adding that the move would make it legal for companies to offer supplemental fertility insurance for the first time. The administration, however, will not mandate that employers offer this coverage, nor will it provide federal subsidies.
Addressing the IVF Cost Barrier
IVF treatment, which involves combining eggs and sperm in a lab to create an embryo, is a costly procedure, with a single cycle typically ranging from $12,000 to $25,000. The pharmaceutical component, which can cost upwards of $5,000, is a major financial hurdle. This 84% discount on key medications is a direct attempt to tackle that cost at the source, offering tangible financial relief to patients who often require multiple cycles.
The focus on IVF treatments also comes after a period of significant national debate over the status of embryos following a 2024 state-level Supreme Court ruling. President Trump has consistently voiced his strong support for IVF as a tool for creating families.
Industry and Advocacy Reaction
Fertility Advocates have largely praised the announcement as a critical, albeit limited, victory. They see the drug price reduction and the push for supplemental insurance as a positive movement toward making treatment more accessible, particularly in states without existing fertility insurance mandates.
However, Critics point out that the initiative falls short of President Trump’s campaign pledge to mandate that the government or insurance companies cover all costs associated with IVF treatment. Since the discounted drugs only represent a portion of the total cost of an IVF cycle, the full financial burden remains substantial.
Merck KGaA CEO, Belen Garijo, stated the agreement is fully aligned with the company’s commitment to patient access and is part of a "long-term value" approach, ensuring their innovative therapies remain within reach for more U.S. families. The commitment to U.S. investment and the expedited FDA review for the drug Pergoveris underscores the strategic nature of the agreement for the global biopharma firm.
The successful negotiation with Merck KGaA demonstrates the administration's continued reliance on the threat of tariffs and the promise of regulatory incentives to force voluntary drug price reductions across the pharmaceutical industry. The market will now be watching to see which company is next to join the TrumpRx platform and what further actions the White House will take to fulfill its promise of universal, affordable fertility care.
In a significant development for the healthcare and fertility industries, former U.S. President Donald Trump and global pharmaceutical company Merck KGaA have announced a deal aimed at reducing the prices of several in-vitro fertilization (IVF) medications. The agreement, revealed during a joint press event on Friday, is being hailed as a “game-changing step” to make fertility treatments more affordable for millions of American families struggling with infertility costs.
According to early details, the partnership will focus on cutting the prices of select fertility medications — including hormone stimulants and ovulation-enhancing drugs — that are often used in IVF cycles. These medications represent one of the highest expenses in fertility treatment, sometimes accounting for 30%–40% of total IVF costs. Under the new initiative, Merck KGaA will offer significant discounts on key fertility drugs, while Trump’s healthcare policy network will assist in expanding access through clinics and insurance partnerships nationwide.
Trump described the deal as a “historic step to help American families grow,” saying that “the dream of having a child should never be limited by the price of medication.” He emphasized that his post-presidential health initiatives continue to focus on affordability and patient choice, mirroring the agenda he pursued during his time in office.
Merck KGaA, the German pharmaceutical and science company, said in a statement that it was proud to collaborate on this affordability plan. The company’s spokesperson noted that the initiative will “strengthen access to reproductive health solutions in a way that ensures both quality and cost transparency.” The partnership reportedly includes a new distribution model designed to lower costs through bulk purchasing and reduced intermediaries — a move that could bring down drug prices by up to 25% in some regions.
Industry experts have reacted positively to the announcement, saying it could spark broader reforms in the fertility sector. With IVF demand on the rise — especially as more couples delay parenthood and rely on assisted reproductive technologies — affordability has become a major concern. According to recent data from the Centers for Disease Control and Prevention (CDC), IVF cycles in the U.S. exceeded 400,000 in 2024, with average costs ranging between $12,000 and $20,000 per treatment cycle.
Healthcare analysts suggest that this new deal could serve as a blueprint for other pharmaceutical companies to follow. If successful, it could influence global pricing structures for fertility treatments, which often vary widely between countries. In the U.S., IVF is rarely covered fully by insurance, and the cost of medications alone can reach $5,000–$7,000 per cycle. The Trump–Merck agreement could bring that figure down substantially.
The announcement also comes amid renewed political debate over healthcare costs in the United States. Trump has increasingly positioned himself as an advocate for lowering drug prices, a policy focus that was central during his administration. While in office, he pushed for price transparency laws and promoted competition in the pharmaceutical industry. The new partnership signals his continued influence in shaping healthcare policy even after leaving the White House.
Critics, however, have cautioned that the success of this initiative will depend on how the discounts are implemented and whether the price reductions truly reach consumers. Past attempts at similar pricing agreements have sometimes failed to deliver tangible benefits for patients due to complex insurance structures and pharmacy markups.
Merck KGaA has committed to publishing quarterly progress updates to ensure accountability and transparency. The company also plans to collaborate with fertility clinics across major states — including California, Texas, and Florida — to monitor the impact of the reduced pricing on treatment accessibility and outcomes.
Clinicians and fertility advocates have welcomed the move, calling it a long-overdue step in addressing the financial strain on couples pursuing IVF. Dr. Emily Harper, a reproductive endocrinologist in New York, noted that “for many patients, the medication cost is the single biggest barrier to treatment. Any meaningful reduction can make the difference between pursuing IVF or giving up on the dream of having a biological child.”
The announcement comes at a time when the IVF industry is under pressure to expand affordability and transparency. Recent surveys show that nearly half of American couples who consider fertility treatments never proceed due to financial reasons. Many turn to overseas clinics in Europe or Asia, where IVF treatments are often less expensive. The Trump–Merck initiative could help stem that trend by making treatments more accessible domestically.
The partnership also highlights Merck KGaA’s growing footprint in the fertility sector. The company already manufactures several leading fertility drugs, including Gonal-f and Ovidrel, used widely in assisted reproductive procedures. With this new pricing strategy, Merck aims to maintain its leadership role while setting a new standard for ethical pricing practices in reproductive health.
In addition to price reductions, Trump’s healthcare advisory team hinted at possible incentives for clinics that participate in the affordability program. These may include grants or subsidies for clinics offering discounted IVF packages, further easing the burden on patients. Discussions are reportedly underway with insurance providers to expand coverage options for fertility medications, an effort that could complement the price-cut deal.
Economists say the long-term implications of this deal could be far-reaching. Lower fertility drug prices may encourage more couples to seek IVF earlier, potentially improving success rates and reducing the number of cycles needed. Moreover, it could enhance the competitiveness of U.S. fertility clinics on the global stage, positioning the country as a leader in accessible reproductive care.
Overall, the Trump–Merck collaboration appears to mark a turning point in the intersection of politics, healthcare policy, and biotechnology. While it remains to be seen how quickly patients will feel the financial impact, the symbolism of the agreement has already resonated across the medical and political landscape. For many, it represents a step toward a future where family-building is not dictated by financial privilege but supported by affordable innovation.
As implementation begins in early 2026, observers will closely monitor how the partnership reshapes the IVF industry. For now, the promise of cheaper fertility drugs brings a new wave of hope to millions of couples aspiring to start a family — a reminder that healthcare reform can still deliver real, human-centered outcomes.
Tags:
Trump IVF Deal, Merck KGaA, Fertility Drug Prices, IVF Cost Reduction, Healthcare Reform, Trump Health Policy, Reproductive Medicine, U.S. Fertility Market, Affordable IVF, Trump News 2025
